Shopping Cart 0
Cart Subtotal
USD 0

ALK-Abello AS (ALK B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK's research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company's products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, Asia-Pacific and other international markets. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS (ALK B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ALK-Abello AS, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Alk Abello Enters into Co-Marketing Agreement with BioCSL 11

ALK-Abello Enters into Agreement with Seqirus 12

ALK-Abello Expands Partnership with Abbott Labs 13

ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 14

ALK Enters Into Co-Promotion Agreement With MSD For Grazax 15

Licensing Agreements 16

Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 16

Equity Offering 17

ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares 17

ALK-Abello Raises USD101.5 Million in Private Placement of B Shares 18

Center Labs to Raise USD96 Million in Private Placement of Shares 19

Center Labs to Raise Funds through Private Placement of Shares 20

ALK-Abello AS-Key Competitors 21

ALK-Abello AS-Key Employees 22

ALK-Abello AS-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 25

Financial Announcements 25

Aug 15, 2018: ALK-Abello: Six-month interim report (Q2) 2018 25

May 04, 2018: ALK Releases Three-month interim report (Q1) 2018 26

Feb 06, 2018: ALK releases its annual report 2017 27

Nov 10, 2017: ALK-Abello: Nine-month interim report (Q3) 2017 28

Aug 16, 2017: ALK-Abello: Six-month interim report (Q2) 2017 29

Aug 16, 2017: ALK: Six-month interim report (Q2) 2017 30

May 09, 2017: ALK-Abello Announces Three-month interim report (Q1) 2017 31

Feb 07, 2017: ALK releases its annual report 2016 32

Corporate Communications 33

Nov 03, 2017: ALK appoints Soren Jelert as new Chief Financial Officer 33

Jul 31, 2017: Management change at ALK 34

Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets 35

Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

ALK-Abello AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ALK-Abello AS, Deals By Therapy Area, 2012 to YTD 2018 8

ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alk Abello Enters into Co-Marketing Agreement with BioCSL 11

ALK-Abello Enters into Agreement with Seqirus 12

ALK-Abello Expands Partnership with Abbott Labs 13

ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 14

ALK Enters Into Co-Promotion Agreement With MSD For Grazax 15

Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 16

ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares 17

ALK-Abello Raises USD101.5 Million in Private Placement of B Shares 18

Center Labs to Raise USD96 Million in Private Placement of Shares 19

Center Labs to Raise Funds through Private Placement of Shares 20

ALK-Abello AS, Key Competitors 21

ALK-Abello AS, Key Employees 22

ALK-Abello AS, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

ALK-Abello AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK's research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company's products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, Asia-Pacific and other international markets. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS (ALK B)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ALK-Abello AS, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Alk Abello Enters into Co-Marketing Agreement with BioCSL 11

ALK-Abello Enters into Agreement with Seqirus 12

ALK-Abello Expands Partnership with Abbott Labs 13

ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 14

ALK Enters Into Co-Promotion Agreement With MSD For Grazax 15

Licensing Agreements 16

Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 16

Equity Offering 17

ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares 17

ALK-Abello Raises USD101.5 Million in Private Placement of B Shares 18

Center Labs to Raise USD96 Million in Private Placement of Shares 19

Center Labs to Raise Funds through Private Placement of Shares 20

ALK-Abello AS-Key Competitors 21

ALK-Abello AS-Key Employees 22

ALK-Abello AS-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 25

Financial Announcements 25

Aug 15, 2018: ALK-Abello: Six-month interim report (Q2) 2018 25

May 04, 2018: ALK Releases Three-month interim report (Q1) 2018 26

Feb 06, 2018: ALK releases its annual report 2017 27

Nov 10, 2017: ALK-Abello: Nine-month interim report (Q3) 2017 28

Aug 16, 2017: ALK-Abello: Six-month interim report (Q2) 2017 29

Aug 16, 2017: ALK: Six-month interim report (Q2) 2017 30

May 09, 2017: ALK-Abello Announces Three-month interim report (Q1) 2017 31

Feb 07, 2017: ALK releases its annual report 2016 32

Corporate Communications 33

Nov 03, 2017: ALK appoints Soren Jelert as new Chief Financial Officer 33

Jul 31, 2017: Management change at ALK 34

Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets 35

Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

ALK-Abello AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ALK-Abello AS, Deals By Therapy Area, 2012 to YTD 2018 8

ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9

ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alk Abello Enters into Co-Marketing Agreement with BioCSL 11

ALK-Abello Enters into Agreement with Seqirus 12

ALK-Abello Expands Partnership with Abbott Labs 13

ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 14

ALK Enters Into Co-Promotion Agreement With MSD For Grazax 15

Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 16

ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares 17

ALK-Abello Raises USD101.5 Million in Private Placement of B Shares 18

Center Labs to Raise USD96 Million in Private Placement of Shares 19

Center Labs to Raise Funds through Private Placement of Shares 20

ALK-Abello AS, Key Competitors 21

ALK-Abello AS, Key Employees 22

ALK-Abello AS, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

ALK-Abello AS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.